Agreement of medical record abstraction and self-report of breast cancer treatment with an extended recall window Journal Article
| Authors: | Reiner, A. S.; Knight, J. A.; John, E. M.; Lynch, C. F.; Malone, K. E.; Liang, X.; Woods, M.; Root, J. C.; Bernstein, J. L. |
| Article Title: | Agreement of medical record abstraction and self-report of breast cancer treatment with an extended recall window |
| Abstract: | Background: Medical record abstraction (MRA) and self-report questionnaires are two methods frequently used to ascertain cancer treatment information. Prior studies have shown excellent agreement between MRA and self-report, but it is unknown how a recall window longer than 3 years may affect this agreement. Methods: The Women’s Environmental Cancer and Radiation Epidemiology (WECARE) Study is a multicenter, population-based case-control study of controls with unilateral breast cancer individually matched to cases with contralateral breast cancer. Participants who were diagnosed with a first primary breast cancer from 1985 to 2008 before the age of 55 years completed a questionnaire that included questions on treatment. First primary breast cancer treatment information was abstracted from the medical record from radiation oncology clinic notes for radiation treatment and from systemic adjuvant treatment reports for hormone therapy and chemotherapy. Agreement between MRA and self-reported treatment was assessed with the kappa statistic and corresponding 95% confidence intervals (CIs). Results: A total of 2808 participants with MRA and self-reported chemotherapy treatment information, 2733 participants with MRA and self-reported hormone therapy information, and 2905 participants with MRA and self-reported radiation treatment information were identified. The median recall window was 12.5 years (range, 2.8–22.2 years). MRA and self-reported treatment agreement was excellent across treatment modalities (kappachemo, 98.5; 95% CI, 97.9–99.2; kappahorm, 87.7; 95% CI, 85.9–89.5; kapparad, 97.9; 95% CI, 97.0–98.7). There was no heterogeneity across recall windows (pchemo =.46; phorm =.40; prad =.61). Conclusions: Agreement between self-reported and MRA primary breast cancer treatment modality information was excellent for young women diagnosed with breast cancer and was maintained even among women whose recall window was more than 20 years after diagnosis. © 2024 American Cancer Society. |
| Keywords: | adult; cancer chemotherapy; controlled study; treatment response; aged; middle aged; case control study; case-control studies; clinical trial; cancer risk; treatment; cancer staging; lymph node dissection; carboplatin; breast cancer; pathology; breast neoplasms; risk factor; self report; docetaxel; cancer hormone therapy; questionnaire; statistical analysis; multicenter study; breast tumor; medical record; tamoxifen; interview; hormonal therapy; estrogen receptor; progesterone receptor; epidemiology; estradiol; adjuvant radiotherapy; ethnicity; therapy; megestrol acetate; population based case control study; raloxifene; recall; mental recall; medical records; kappa statistics; structured questionnaire; self-report; humans; human; female; article; surveys and questionnaires |
| Journal Title: | Cancer |
| Volume: | 131 |
| Issue: | 1 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2025-01-01 |
| Start Page: | e35459 |
| Language: | English |
| DOI: | 10.1002/cncr.35459 |
| PUBMED: | 38941510 |
| PROVIDER: | scopus |
| PMCID: | PMC11680718 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Anne Reiner -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work